In this trial, tumor uptake of the radiotracer—a zirconium‐89‐labeled anti‐DLL3 antibody ([89Zr]Zr‐DFO‐SC16.56)—showed high concordance with DLL3 protein expression confirmed by IHC [288]. This evidence concerns the gene DLL3 and neoplasm.